With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to ...
Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.
Zacks.com on MSN3d
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & MoreFDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research ...
Ebglyss' approval highlights the opportunity that exists in the AD space, and may have potential advantages in efficacy and ...
Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY ...
AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD). The ...
Activist investor Starboard Value has taken a roughly $1 billion stake in Pfizer and wants the drugmaker to make changes ...
The US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback